The current study revealed that a subset of effector CD8+ T cells characterized as CD38+HLA-DR+CD8+ existed in both the peripheral blood and the tumor microenvironment, which indicated that the immune system of patients with glioma could recognize the tumor cells at an early stage. Here, CD38 is linked to neoplasm.